ABSTRACT

The history of patent harmonization is a story of dynamic actors, whose interactions with established structures shaped the patent regime. From the inception of the trade regime to include intellectual property (IP) rights to the present, this book documents the role of different sets of actors – states, transnational business corporations, or civil society groups – and their influence on the structures – such as national and international agreements, organizations, and private entities – that have caused changes to healthcare and access to medication. Presenting the debates over patents, trade, and the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement), as it galvanized non-state and nonbusiness actors, the book highlights how an alternative framing and understanding of pharmaceutical patent rights emerged: as a public issue, instead of a trade or IP issue. The book thus offers an important analysis of the legal and political dynamics through which the contest for access to lifesaving medication has been, and will continue to be, fought.

In addition to academics working in the areas of international law, development, and public health, this book will also be of interest to policy makers, state actors, and others with relevant concerns working in nongovernmental and international organizations.

chapter |22 pages

Introduction

Access to Medicines and TRIPS Agreement: A Mapping of the Tradescape

part I|122 pages

International Norm Setting and Patent Metamorphosis

chapter 241|19 pages

World Trade Organization

A Barrier to Global Public Health?

chapter 2|22 pages

World Health Organization

Contributions to Access to Health and TRIPS Agreement Discourse

chapter 3|16 pages

From TRIPS to Access to Medicines

What's There in Between?

chapter 4|12 pages

Free Trade Agreements

Longer, Further, Deeper Impact on Pharmaceutical Patents

chapter 5|17 pages

From the TPP to USMCA

A High-Powered Battle over Biologics

chapter 6|22 pages

African Union Continental Free Trade Area

Opportunities for New Regional Discourse?

part II|148 pages

State Action and Access to Medicines Debate

chapter 1468|25 pages

Brazil

Patent Barriers and Access to Medicines Through the Public Health System*

chapter 9|17 pages

From Struggle to Surge

China's TRIPS Experience and Its Lessons for Access to Medicines

chapter 10|24 pages

Canada

Access to Medicines in High-income Countries

chapter 11|22 pages

India

Pharmaceutical Patents and Evergreen Battle for Access to Medicines

chapter 13|22 pages

Thailand

Shooting Star for Access to Medicines Through Compulsory Licensing

chapter 14|19 pages

United States

Unilateral Norm Setting Using Special 301

part III|190 pages

Global Patterns and Emerging Issues

chapter 29415|32 pages

Access to Medicines Activism

Collaboration, Conflicts, and Complementarities

chapter 16|17 pages

GTPI

Experiences to Overcome IP Barriers to Increase Access to Medicines

chapter 17|18 pages

Private Sector

Right to Health Responsibilities of Pharmaceutical Companies

chapter 18|17 pages

Competition

Can Excessive Pricing be Fixed Through Abuse of Dominant Position?

chapter 20|26 pages

Innovation Policies

Roadblocks to Establishing Sustainable Pharmaceutical Innovation Policies

chapter 21|15 pages

Not Just Patents and Data Exclusivity

The Role of Trademarks in Integrated IP Strategy – Where Lies the Public Interest?

chapter 22|18 pages

Indigenous Knowledge

Bridging with Modern Medicine

chapter 23|19 pages

Digital Divide and Access to Medicines

The Debate

part IV|14 pages

COVID-19 and Access to Medicines